Potential Complications Associated with Normothermic Lonidamine Infusion and with Systemic Acidosis in Dogs Receiving Lonidamine During Whole Body Hyperthermia (Wbh)

References

• Besner J.-G., Leclaire R., Band P. R., Deschamps M., De Sanctis A. J., Catanese B. Pharmacokinetics of lonidamine after oral administration in cancer patients. Oncology 1984; 41: 48–52, (suppl 1)
   PubMed Web of Science ®Google Scholar
• Bloch W. E., Lokeshwar B. L., Ferrell S. M., Block N. L. Enhancement of hyperthermic toxicity by lonidamine in the Dunning R3327G rat prostatic adenocarcinoma. The Prostrate 1994; 24: 131–138
   PubMed Web of Science ®Google Scholar
• Cavaliere R., Di Filippo F., Varanese A., Carlini S., Calabro A., Aloe L., Piarulli L. Lonidamine and hyperthermia: Clinical experience in Melanoma. Preliminary results. Oncology 1984; 41: 116–120, (suppl 1)
   PubMed Web of Science ®Google Scholar
• Chitnis M., Adwankar M. Potentiation of adriamycin cytoxocity in P388 murine leukemia sensitive and resistant to adriamycin by use of lonidamine and hyperthermia. Turmori 1986; 72: 469–473
   PubMed Web of Science ®Google Scholar
• DeAngelis L. M., Currie V. E., Kim J.-H., Krol G., O'Hehir M. A., Farag F. M., Young C. W., Posner J. B. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. Journal of Neuro-Oncology 1989; 7: 241–247
   PubMed Web of Science ®Google Scholar
• De Fabritiis P., Sandrelli A., Covelli A., Simone F., De Felice L., Pulsoni A., Zupi G., Mandelli F. In vitro pharmacological purging of human bone marrow is enhanced by lonidamine. Experimental and Molecular Pathology 1989; 50: 210–219
   PubMed Web of Science ®Google Scholar
• De Martino C., Malorni W., Accinni L., Rosati R., Nista A., Formisano G., Silvestrini B., Arcancia G. Cell membrane changes induced by lonidamine in human erythrocytes and T-lymphocytes, and Ehrlich ascites tumor cells. Experimental and Molecular Pathology 1987; 46: 15–30
   PubMed Web of Science ®Google Scholar
• Floridi A., Gentile F. P., Bruno T., Delpino A., Iacobini C., Paggi M. G., Castiglione S., Benassi M. Thermal behavior of a human glioma cell line and its response to combinations of hyperthermia and lonidamine. Oncology Research 1993; 5: 1–10
   PubMed Web of Science ®Google Scholar
• Gallo-Curcio C., Verturo I., Rinaldi M., Impiombato F. A., Del Vecchio M. R., Tonachella R., Tropea F., Antilli A., Ciottoli G. B., De Gregorio M., Salvati F. Chemotherapy/radiation therapy plus/minus lonidamine in the treatment of non-small cell lung cancer (limited disease): Preliminary results. Seminars in Oncology 1988; 15: 26–31, (suppl 7)
   PubMed Web of Science ®Google Scholar
• Gatzemeier U., Toomes H., Picollo R., Christoffel V., Lücker P. W., Ulmer J. Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer. Arzneimmittel-Forschung [Drug Research] 1991; 41: 436–439
   PubMed Web of Science ®Google Scholar
• Hahn G. M., Van Kersen L., Silvestrini B. Inhibition of the recovery from potentially lethal damage by lonidamine. British Journal of Cancer 1984; 50: 657–660
   PubMed Web of Science ®Google Scholar
• Jones A. L., Hardy J. R., Newell D. R., Smith I. E. Clinical study and pharmacokinetics of lonidamine in advance non-small cell lung cancer. European Journal of Cancer 1991; 27: 519
   PubMed Web of Science ®Google Scholar
• Kim J. H., Alfieri A. A., Kim S. H., Young C. W. Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Research 1986; 46: 1120–1123
   PubMed Web of Science ®Google Scholar
• Kim J. H., Alfieri A., Kim S. H., Young C. W., Silvestrini B. Radiosensitization of Meth-A fibrosarcoma in mice by lonidamine. Oncology 1984b; 41: 36–38, (suppl 1)
   PubMed Web of Science ®Google Scholar
• Kim J. H., Kim S. H., Alfieri A., Young C. W., Silvestrini B. Lonidamine: A hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo. Oncology 1984a; 41: 30–35, (suppl 1)
   PubMed Web of Science ®Google Scholar
• Kim J. H., Kim S. H., He S. Q., Alfieri A. A., Young C. W. Potentiation of radiation effects on multicellular tumor spheroids (MTS) of HeLa cells by lonidamine. International Journal of Radiation: Oncology-Biology-Physics 1989; 16: 1277–1280
   PubMed Web of Science ®Google Scholar
• Ko D., Raaphorst P., Feeley M. M., Danjoux C. E., Maroun J. A., Evans W. K. The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines. Anticancer Research 1991; 11: 235–240
   PubMed Web of Science ®Google Scholar
• Maloreni W., Arancia G., De Martino C., Nista A., Accinni L., Masella R., Cantafora A. On the mechanism of action of lonidamine: A study on human erythrocyte membrane. Experimental and Molecular Pathology 1988; 49: 361–372
   PubMed Web of Science ®Google Scholar
• Mansi J. L., De Graeff A., Newell D. R., Glaholm J., Button D., Leach M. O., Payne G., Smith I. E. A phase II clinical and pharmacokinetic study of lonidamine in patients with advanced breast cancer. British Journal of Cancer 1991; 64: 593–597
   PubMed Web of Science ®Google Scholar
• Meyer R. E., Page R. L., Thrall D. E., Dewhirst M. W., Vose D. L. Determination of continuous atracurium infusion rate in dogs undergoing whole-body hyperthermia. Cancer Research 1986; 46: 5599–5601
   PubMed Web of Science ®Google Scholar
• Newell D. R., Mansi J., Hardy J., Button D., Jenns K., Smith I. E., Picollo R., Cantanese B. Seminars in Oncology 1991; 18: 11–17
   PubMed Web of Science ®Google Scholar
• Ning S., Hahn G. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells. in vitro. Cancer Research 1990; 50: 7867–7870
   PubMed Web of Science ®Google Scholar
• Page R. L., Thrall D. E. Hyperthermia and chemotherapy: Contributions from canine studies. Hyperthermia and Oncology, M. Urano, E. Douple. VSP BV, Utrecht 1994; Vol. 4: 205–217
   Google Scholar
• Page R. L., Meyer R. E., Thrall D. E., Dewhirst M. W. Cardiovascular and metabolic response of tumour-bearing dogs to whole body hyperthermia. International Journal of Hyperthermia 1987; 3: 513–525
   PubMed Web of Science ®Google Scholar
• Price G. S., Page R. L., Riviere J. E., Cline J. M., Frazier D. L., Thrall D. E. Pharmacokinetics and toxicity of lonidamine and doxorubicin in dogs undergoing whole body hyperthermia. International Journal of Hyperthermia 1995b; 11: 545–559
   PubMed Web of Science ®Google Scholar
• Price G. S., Page R. L., Riviere J. E., Cline J. M., Thrall D. E. Effect of whole body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs. International Journal of Hyperthermia 1995a; 11: 531–544
   PubMed Web of Science ®Google Scholar
• Price G. S., Page R. L., Riviere J. E., Cline J. M., Thrall D. E. Pharmacokinetics and toxicity of oral intravenous lonidamine in dogs. Cancer Chemotherapy and Pharmacology 1996; 2: 129–135
   Google Scholar
• Privitera G., Ciottoli G. B., Patanè C., Palmucci T., Tafuri G., Marletta F., De Luca B., Magnani F., De Gregorio M., Greco S. Phase II double-blind randomized study of lonidamine and radiotherapy in epidermoid carcinoma of the lung. Radiotherapy and Oncology 1987; 10: 285–290
   PubMed Web of Science ®Google Scholar
• Raaphorst G. P., Feeley M. M., Martin L., Danjoux C. E., Maroun J., DeSanctis A. J., Ko D. Enhancement of sensitivity to hyperthermia by lonidamine in human cancer cells. International Journal of Hyperthermia 1991b; 7: 763–772
   PubMed Web of Science ®Google Scholar
• Raaphorst G. P., Ko D., Feeley M. M., Danjoux C. E., Maroun J. A., Evans W. K. The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines. Anticancer Research 1991a; 11: 41–48
   PubMed Web of Science ®Google Scholar
• Robbins H. I., Longo W. L., Lagoni R. K., Neville A. L., Hugander A., Schmitt C. L., Rigg C. Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. Cancer Research 1988; 48: 6587–6592
   PubMed Web of Science ®Google Scholar
• Robins H. I., Longo W. L., Steeves R. A., Cohen J. D., Schmitt C. L., Neville A. J., O'Keefe S., Lagoni R., Riggs C. Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: A report of two pilot clinical trials and laboratory investigations. International Journal of Radiation: Oncology-Biology-Physics 1990; 18: 909–920
   PubMed Web of Science ®Google Scholar
• Rotin D., Tannock I. F. The effect of the drug lonidamine on Chinese Hamster Ovary cells in vitro and on experimental tumors. International Journal of Radiation: Oncology-Biology-Physics 1984; 10: 1595–1598
   PubMed Web of Science ®Google Scholar
• Silvestrini B., Hahn G. M., Ciolo V., De Martini C. Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumor systems. British Journal of Cancer 1983; 41: 221–231
   Google Scholar
• Silvestrini R., Zaffaroni N., Villa R., Orlandi L., Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. International Journal of Cancer 1992; 52: 813–817
   PubMed Web of Science ®Google Scholar
• Tanaka J., Teicher B. A., Herman T. S., Holden S. A., Dezube B., Frei E. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity. in vivo. International Journal of Cancer 1991; 48: 631–637
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Herman T. S. Antitumor chemotherapy with hyperthermia and radiation trimodality therapy. Hyperthermia and Oncology, M. Urano, E. Douple. VSP BV, Utrecht 1994; Vol. 4: 115–167
   Google Scholar
• Teicher B. A., Holden S. A., Ara G., Menon K. Whole-body hyperthermia and lonidamine as adjuvant therapy to treatment with cisplatin with or without local radiation in mouse bearing the Lewis lung carcinoma. International Journal of Hyperthermia 1995; 11: 637–645
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Herman T. S., Holden S. A., Eplbaum R., Liu S., Frei E. Lonidamine as a modulator of alkylating agent activity in vitro and. in vivo. Cancer Research 1991a; 51: 780–784
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Holden S. A., Herman T. S., Frei E. Modulation of alkylating agents by lonidamine. in vivo. Seminars in Oncology 1991b; 18: 7–10
   PubMed Web of Science ®Google Scholar
• Thrall D. E., Page R. L., Dewhirst M. W., Meyer R. E., Hoopes P. J., Kornegay J. N. Temperature measurements in normal and tumor tissue of dogs undergoing whole body hyperthermia. Cancer Research 1986; 46: 6229–6235
   PubMed Web of Science ®Google Scholar
• Villa R., Zaffaroni N., Orlandi L., Bearzatto A., Costa A., Silvestrini R. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. European Journal of Cancer 1994; 30A: 1534–1540
   PubMed Web of Science ®Google Scholar
• Weinerman B. H., Eisenhauer E. A., Besner J.-G., Coppin C. M., Stewart D., Band P. R. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: A National Cancer Institute of Canada Clinical Trials Group study. Cancer Treatment Reports 1986; 70: 751–754
   PubMedGoogle Scholar
• Young C. W., Currie V. E., Kim J. H., O'Hehir M. A., Farag F. M., Kinahan J. E. Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer. Oncology 1984; 41: 60–65, (suppl 1)
   PubMed Web of Science ®Google Scholar
• Zaffaroni N., Villa R., Orlandi L., Vaglini M., Silvestrini R. Combined effects of Ionidamine and hyperthermia on malignant melanoma and lung carcinoma surgical specimens. Anticancer Research 1992; 12: 247–25
   PubMed Web of Science ®Google Scholar
• Zupi G., Greco C., Laudonio N., Benassi M., Silverstini B. In vitro and in vivo potential by lonidamine of the antitumor effect of adriamycin. Anticancer Research 1986; 6: 1245–1250, (suppl 1)
   PubMed Web of Science ®Google Scholar